Author

P. Phojanakong

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 6 Approach:experimental assay· 5 Organism:human· 5 Research Focus:drug response / drug discovery· 4 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:deep learning· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

V. Steri· 5 shared C. Kasap· 3 shared E. Stieglitz· 3 shared F. Salangsang· 3 shared Y.-H. T. Lin· 3 shared A. Kang· 2 shared A. P. Wiita· 2 shared A. Wiita· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

V. Steri

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Chemoproteomics reveals immunogenic and tumor-associated cell surface substrates of ectokinase CK2α

C. S. Delaveris, S. Kong, J. Glasgow, R. P. Loudermilk, L. L. Kirkemo, F. Zhao, F. Salangsang, P. Phojanakong, J. A. C. Serrano, V. Steri, J. A. Wells

The paper uses chemoproteomics to identify immunogenic cell surface substrates of CK2α in the tumor microenvironment, showing that extracellular phosphorylation can generate immunogenic antigens.

bioRxiv · Mar 20, 2024Biochemistry

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells

C. Kasap, A. Izgutdina, B. Patino-Escobar, A. Kang, N. Chilakapati, N. Akagi, H. Johnson, T. Rashid, J. Werner, A. Barpanda, H. Geng, Y.-H. T. Lin, S. Rampersaud, D. Gil-Alos, A. Sobh, , A. Wiita

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.

bioRxiv · Feb 24, 2024Cancer Biology

Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in FLT3- and KIT- Mutant AML

B. Popescu, C. Stahlhut, T. C. Tarver, S. Wishner, B. J. Lee, C. A. C. Peretz, C. Luck, P. Phojanakong, J. A. Camara Serrano, H. Hongo, J. M. Rivera, S. Xirenayi, J. A. Chukinas, V. Steri, S. K. Tasian, , C. C. Smith

This study shows that combining SHP2 and BCL2 inhibition synergistically kills FLT3- and KIT-mutant AML cells and xenografts.

bioRxiv · Dec 1, 2022 · PreprintCancer Biology

Structural surfaceomics reveals an AML-specific conformation of Integrin-β2 as a CAR-T therapy target

K. Mandal, G. Wicaksono, C. Yu, J. J. Adams, M. R. Hoopmann, W. C. Temple, B. P. Escobar, M. Gorelik, C. H. Ihling, M. A. Nix, A. Naik, E. Ramos, C. Kasap, V. Steri, J. A. C. Serrano, , A. P. Wiita

The paper identifies an AML-specific conformation of Integrin-β2 using structural surfaceomics and demonstrates its targeting by CAR-T cells.

bioRxiv · Oct 10, 2022 · PreprintCancer Biology

Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

P. Choudhry, C. Kasap, B. Patino Escobar, O. Gugliemini, H. Geng, V. Sarin, A. Kang, A. Kishishita, S. Rampersaud, L. Sarah, Y.-H. T. Lin, N. Paranjape, P. Ramkumar, M. Marcoulis, D. Wang, , A. Wiita

This study uses multi-omics approaches to identify regulators of CD38 surface expression in multiple myeloma and assess the impact of therapies on CD38 levels and signaling.

bioRxiv · Aug 4, 2021 · PreprintCancer Biology

Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

H. H.-L. Huang, I. D. Ferguson, A. M. Thornton, C. Y. T. Lam, Y.-H. T. Lin, P. Bastola, P. Choudhry, M. C. Mariano, M. D. Marcoulis, J. Malato, P. Phojanakong, T. G. Martin, J. L. Wolf, S. W. Wong, N. Shah, , A. P. Wiita

The paper shows proteasome inhibitors modulate splicing in multiple myeloma, revealing spliceosome inhibition as a therapeutic target.

bioRxiv · Feb 3, 2019Cancer Biology